{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:03:10Z","timestamp":1790244190619,"version":"4.1.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T00:00:00Z","timestamp":1579219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Myriad RBM Inc."},{"DOI":"10.13039\/100006436","name":"Celgene Corporation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Finding biomarkers that provide shared link between disease severity, drug-induced pharmacodynamic effects and response status in human trials can provide number of values for patient benefits: elucidating current therapeutic mechanism-of-action, and, back-translating to fast-track development of next-generation therapeutics. Both opportunities are predicated on proactive generation of human molecular profiles that capture longitudinal trajectories before and after pharmacological intervention. Here, we present the largest plasma proteomic biomarker dataset available to-date and the corresponding analyses from placebo-controlled Phase III clinical trials of the phosphodiesterase type 4 inhibitor apremilast in psoriasis (PSOR), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) from 526 subjects overall. Using approximately 150 plasma analytes tracked across three time points, we identified IL-17A and KLK-7 as biomarkers for disease severity and apremilast pharmacodynamic effect in psoriasis patients. Combined decline rate of KLK-7, PEDF, MDC and ANGPTL4 by Week 16 represented biomarkers for the responder subgroup, shedding insights into therapeutic mechanisms. In ankylosing spondylitis patients, IL-6 and LRG-1 were identified as biomarkers with concordance to disease severity. Apremilast-induced LRG-1 increase was consistent with the overall lack of efficacy in ankylosing spondylitis. Taken together, these findings expanded the mechanistic knowledge base of apremilast and provided translational foundations to accelerate future efforts including compound differentiation, combination, and repurposing.<\/jats:p>","DOI":"10.1038\/s41598-020-57542-5","type":"journal-article","created":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T06:03:13Z","timestamp":1579240993000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Large-scale Analyses of Disease Biomarkers and Apremilast Pharmacodynamic Effects"],"prefix":"10.1038","volume":"10","author":[{"given":"Irina V.","family":"Medvedeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew E.","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Eisinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel T.","family":"LaBrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W. B.","family":"Trotter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,17]]},"reference":[{"key":"57542_CR1","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1111\/j.1365-2133.2007.07935.x","volume":"156","author":"S-E Chang","year":"2007","unstructured":"Chang, S.-E., Han, S.-S., Jung, H.-J. & Choi, J.-H. Neuropeptides and their receptors in psoriatic skin in relation to pruritus. British Journal of Dermatology 156, 1272\u20131277 (2007).","journal-title":"British Journal of Dermatology"},{"key":"57542_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2340\/00015555-0764","volume":"90","author":"TM Ljosaa","year":"2010","unstructured":"Ljosaa, T. M. et al. Skin pain and discomfort in psoriasis: an exploratory study of symptom prevalence and characteristics. Acta Derm. Venereol. 90, 39\u201345 (2010).","journal-title":"Acta Derm. Venereol."},{"issue":"Suppl 2","key":"57542_CR3","first-page":"i14","volume":"64","author":"DD Gladman","year":"2005","unstructured":"Gladman, D. D., Antoni, C., Mease, P., Clegg, D. O. & Nash, P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann. Rheum. Dis. 64(Suppl 2), i14\u201317 (2005).","journal-title":"Ann. Rheum. Dis."},{"key":"57542_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/247553031016a00403","volume":"16","author":"K Busse","year":"2010","unstructured":"Busse, K. & Liao, W. Which Psoriasis Patients Develop Psoriatic Arthritis? Psoriasis Forum 16, 17\u201325 (2010).","journal-title":"Psoriasis Forum"},{"key":"57542_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","volume":"3","author":"JM Moll","year":"1973","unstructured":"Moll, J. M. & Wright, V. Psoriatic arthritis. Semin. Arthritis Rheum. 3, 55\u201378 (1973).","journal-title":"Semin. Arthritis Rheum."},{"key":"57542_CR6","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1056\/NEJMra1406182","volume":"374","author":"JD Taurog","year":"2016","unstructured":"Taurog, J. D., Chhabra, A. & Colbert, R. A. Ankylosing Spondylitis and Axial Spondyloarthritis. N. Engl. J. Med. 374, 2563\u20132574 (2016).","journal-title":"N. Engl. J. Med."},{"key":"57542_CR7","doi-asserted-by":"publisher","unstructured":"Woo, Y. R., Cho, D. H. & Park, H. J. Molecular mechanisms and management of a cutaneous inflammatory disorder: Psoriasis. International Journal of Molecular Sciences 18, https:\/\/doi.org\/10.3390\/ijms18122684 (2017).","DOI":"10.3390\/ijms18122684"},{"key":"57542_CR8","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale, D. J. & Fearon, U. The pathogenesis of psoriatic arthritis. The Lancet 391, 2273\u20132284 (2018).","journal-title":"The Lancet"},{"key":"57542_CR9","doi-asserted-by":"publisher","first-page":"e163","DOI":"10.1038\/cti.2017.49","volume":"6","author":"Z Li","year":"2017","unstructured":"Li, Z. & Brown, M. A. Progress of genome-wide association studies of ankylosing spondylitis. Clinical & Translational Immunology 6, e163, https:\/\/doi.org\/10.1038\/cti.2017.49 (2017).","journal-title":"Clinical & Translational Immunology"},{"key":"57542_CR10","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","volume":"83","author":"P Schafer","year":"2012","unstructured":"Schafer, P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochemical Pharmacology 83, 1583\u20131590 (2012).","journal-title":"Biochemical Pharmacology"},{"key":"57542_CR11","doi-asserted-by":"publisher","unstructured":"Schafer, P., Chen, P., Fang, L., Wang, A. & Chopra, R. The Pharmacodynamic Impact of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, on Circulating Levels of Inflammatory Biomarkers in Patients with Psoriatic Arthritis: Substudy Results from a Phase III, Randomized, Placebo-Controlled Trial (PALACE 1). Journal of Immunology Research 2015, https:\/\/doi.org\/10.1155\/2015\/906349 (2015).","DOI":"10.1155\/2015\/906349"},{"key":"57542_CR12","first-page":"835","volume":"17","author":"C Pincelli","year":"2018","unstructured":"Pincelli, C., Schafer, P. H., French, L. E., Augustin, M. & Krueger, J. G. Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis. J. Drugs Dermatol 17, 835\u2013840 (2018).","journal-title":"J Drugs Dermatol"},{"key":"57542_CR13","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/2475530318788934","volume":"3","author":"A Alomran","year":"2018","unstructured":"Alomran, A. et al. Apremilast in combination with an interleukin 17A inhibitor in the treatment of recalcitrant palmoplantar psoriasis: A chart review. Journal of Psoriasis and Psoriatic Arthritis 3, 122\u2013125, https:\/\/doi.org\/10.1177\/2475530318788934 (2018).","journal-title":"Journal of Psoriasis and Psoriatic Arthritis"},{"key":"57542_CR14","doi-asserted-by":"publisher","first-page":"AB47","DOI":"10.1016\/j.jaad.2017.04.201","volume":"76","author":"JG Krueger","year":"2017","unstructured":"Krueger, J. G. et al. Apremilast reduces IL-17F, IL-17A, IL-22, and TNF- plasma protein levels in patients with moderate to severe plaque psoriasis: Pharmacodynamic and correlative results from phase 2\/3 studies. Journal of the American Academy of Dermatology 76, AB47, https:\/\/doi.org\/10.1016\/j.jaad.2017.04.201 (2017).","journal-title":"Journal of the American Academy of Dermatology"},{"key":"57542_CR15","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.jaci.2018.05.039","volume":"142","author":"S Garcet","year":"2018","unstructured":"Garcet, S., Nograles, K., Correa da Rosa, J., Schafer, P. H. & Krueger, J. G. Synergistic cytokine effects as apremilast response predictors in patients with psoriasis. J. Allergy Clin. Immunol. 142, 1010\u20131013 (2018).","journal-title":"J. Allergy Clin. Immunol."},{"key":"57542_CR16","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.4049\/jimmunol.1101201","volume":"187","author":"F Ye","year":"2011","unstructured":"Ye, F. et al. Retinal self-antigen induces a predominantly Th1 effector response in Axl and Mertk double-knockout mice. J. Immunol. 187, 4178\u20134186 (2011).","journal-title":"J. Immunol."},{"key":"57542_CR17","doi-asserted-by":"publisher","unstructured":"Wium, M., Paccez, J. D. & Zerbini, L. F. The Dual Role of TAM Receptors in Autoimmune Diseases and Cancer: An Overview. Cells 7, https:\/\/doi.org\/10.3390\/cells7100166 (2018).","DOI":"10.3390\/cells7100166"},{"key":"57542_CR18","doi-asserted-by":"publisher","first-page":"6848430","DOI":"10.1155\/2017\/6848430","volume":"2017","author":"GJ Zhao","year":"2017","unstructured":"Zhao, G. J. et al. Growth Arrest-Specific 6 Enhances the Suppressive Function of CD4+CD25+ Regulatory T Cells Mainly through Axl Receptor. Mediators Inflamm. 2017, 6848430, https:\/\/doi.org\/10.1155\/2017\/6848430 (2017).","journal-title":"Mediators Inflamm."},{"key":"57542_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/srep42695","volume":"7","author":"J Li","year":"2017","unstructured":"Li, J. et al. Therapeutic effects of human adipose tissue-derived stem cell (hADSC) transplantation on experimental autoimmune encephalomyelitis (EAE) mice. Sci Rep 7, 42695, https:\/\/doi.org\/10.1038\/srep42695 (2017).","journal-title":"Sci Rep"},{"key":"57542_CR20","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.4049\/jimmunol.178.7.4335","volume":"178","author":"H Novak","year":"2007","unstructured":"Novak, H. et al. CCL23 Expression Is Induced by IL-4 in a STAT6-Dependent Fashion. The Journal of Immunology 178, 4335\u20134341, https:\/\/doi.org\/10.4049\/jimmunol.178.7.4335 (2007).","journal-title":"The Journal of Immunology"},{"key":"57542_CR21","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3389\/fcimb.2017.00176","volume":"7","author":"F Arruda-Silva","year":"2017","unstructured":"Arruda-Silva, F. et al. Human Neutrophils Produce CCL23 in Response to Various TLR-Agonists and TNF. Front Cell Infect Microbiol 7, 176 (2017).","journal-title":"Front Cell Infect Microbiol"},{"key":"57542_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-09207-z","volume":"7","author":"PM Brunner","year":"2017","unstructured":"Brunner, P. M. et al. The atopic dermatitis blood signature is characterized by increases in inflammatory and cardiovascular risk proteins. Sci Rep 7, 8707, https:\/\/doi.org\/10.1038\/s41598-017-09207-z (2017).","journal-title":"Sci Rep"},{"key":"57542_CR23","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.4049\/jimmunol.180.3.1913","volume":"180","author":"AS Haider","year":"2008","unstructured":"Haider, A. S. et al. Identification of cellular pathways of \u201cType 1,\u201d Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. The Journal of Immunology 180, 1913\u20131920 (2008).","journal-title":"The Journal of Immunology"},{"key":"57542_CR24","doi-asserted-by":"publisher","first-page":"P73","DOI":"10.1016\/S1471-4906(02)00028-5","volume":"24","author":"B Uchanska-Ziegler","year":"2003","unstructured":"Uchanska-Ziegler, B. & Ziegler, A. Ankylosing spondylitis: a2 \u03b22m-deposition disease? Trends Immunol. 24, P73\u201376 (2003).","journal-title":"Trends Immunol."},{"key":"57542_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/j.1600-0625.2006.00406.x","volume":"15","author":"T Hohwy","year":"2006","unstructured":"Hohwy, T. et al. Surfactant protein d in atopic dermatitis and psoriasis. Experimental Dermatology 15, 168\u2013174 (2006).","journal-title":"Experimental Dermatology"},{"key":"57542_CR26","doi-asserted-by":"publisher","first-page":"R188","DOI":"10.1186\/ar4378","volume":"15","author":"KE Magee","year":"2013","unstructured":"Magee, K. E. et al. Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma. Arthritis Res. Ther. 15, R188 (2013).","journal-title":"Arthritis Res. Ther."},{"key":"57542_CR27","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1002\/art.39800","volume":"68","author":"F Abji","year":"2016","unstructured":"Abji, F., Pollock, R. A., Liang, K., Chandran, V. & Gladman, D. D. Brief report: Cxcl10 is a possible biomarker for the development of psoriatic arthritis among patients with psoriasis. Arthritis & Rheumatology 68, 2911\u20132916, https:\/\/doi.org\/10.1002\/art.39800 (2016).","journal-title":"Arthritis & Rheumatology"},{"key":"57542_CR28","unstructured":"Antonelli, A. et al. High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthtritis. Clin. Exp. Rheumatol. 27, 22\u20137 (2009)."},{"key":"57542_CR29","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1093\/bioinformatics\/btq503","volume":"26","author":"EJ Fertig","year":"2010","unstructured":"Fertig, E. J., Ding, J., Favorov, A. V., Parmigiani, G. & Ochs, M. F. CoGAPS: an R\/C++ package to identify patterns and biological process activity in transcriptomic data. Bioinformatics 26, 2792\u20132793 (2010).","journal-title":"Bioinformatics"},{"key":"57542_CR30","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1093\/bioinformatics\/btx058","volume":"33","author":"GL Stein-O\u2019Brien","year":"2017","unstructured":"Stein-O\u2019Brien, G. L. et al. PatternMarkers & GWCoGAPS for novel data-driven biomarkers via whole transcriptome NMF. Bioinformatics 33, 1892\u20131894 (2017).","journal-title":"Bioinformatics"},{"key":"57542_CR31","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/j.1600-0625.2007.00562.x","volume":"16","author":"N Komatsu","year":"2007","unstructured":"Komatsu, N. et al. Human tissue kallikrein expression in the stratum corneum and serum of atopic dermatitis patients. Exp. Dermatol. 16, 513\u2013519 (2007).","journal-title":"Exp. Dermatol."},{"key":"57542_CR32","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.0022-202X.2004.22708.x","volume":"123","author":"Y Vasilopoulos","year":"2004","unstructured":"Vasilopoulos, Y. et al. Genetic association between an AACC insertion in the 3\u2019UTR of the stratum corneum chymotryptic enzyme gene and atopic dermatitis. J. Invest. Dermatol. 123, 62\u201366 (2004).","journal-title":"J. Invest. Dermatol."},{"key":"57542_CR33","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s004030050393","volume":"291","author":"E Ekholm","year":"1999","unstructured":"Ekholm, E. & Egelrud, T. Stratum corneum chymotryptic enzyme in psoriasis. Arch. Dermatol. Res. 291, 195\u2013200 (1999).","journal-title":"Arch. Dermatol. Res."},{"key":"57542_CR34","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.phrs.2011.02.001","volume":"63","author":"N Marjanovic","year":"2011","unstructured":"Marjanovic, N. et al. Macrolide antibiotics broadly and distinctively inhibit cytokine and chemokine production by COPD sputum cells in vitro. Pharmacol. Res. 63, 389\u2013397 (2011).","journal-title":"Pharmacol. Res."},{"key":"57542_CR35","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul, C. et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br. J. Dermatol. 173, 1387\u20131399 (2015).","journal-title":"Br. J. Dermatol."},{"key":"57542_CR36","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh, A. et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann. Rheum. Dis. 73, 1020\u20131026 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"57542_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v033.i01","volume":"33","author":"T Friedman","year":"2010","unstructured":"Friedman, T., Hastie, J. & Tibshirani, R. Regularization paths for generalized linear models via coordinate descent. Journal of Statistical Software 33, 1\u201322 (2010).","journal-title":"Journal of Statistical Software"},{"key":"57542_CR38","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47, https:\/\/doi.org\/10.1093\/nar\/gkv007 (2015).","journal-title":"Nucleic Acids Res."},{"key":"57542_CR39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nmeth.3252","volume":"12","author":"W Huber","year":"2015","unstructured":"Huber, W. et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat. Methods 12, 115\u2013121 (2015).","journal-title":"Nat. Methods"},{"key":"57542_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-7-175","volume":"7","author":"G Wang","year":"2006","unstructured":"Wang, G., Kossenkov, A. V. & Ochs, M. F. LS-NMF: a modified non-negative matrix factorization algorithm utilizing uncertainty estimates. BMC Bioinformatics 7, 175 (2006).","journal-title":"BMC Bioinformatics"},{"key":"57542_CR41","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.2217\/14622416.8.11.1521","volume":"8","author":"R Frijters","year":"2007","unstructured":"Frijters, R., Verhoeven, S., Alkema, W., van Schaik, R. & Polman, J. Literature-based compound profiling: application to toxicogenomics. Pharmacogenomics 8, 1521\u20131534 (2007).","journal-title":"Pharmacogenomics"},{"key":"57542_CR42","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","volume":"30","author":"R Edgar","year":"2002","unstructured":"Edgar, R., Domrachev, M. & Lash, A. E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30, 207\u2013210 (2002).","journal-title":"Nucleic Acids Res."},{"key":"57542_CR43","doi-asserted-by":"publisher","unstructured":"Leek, J. T. et al. sva: Surrogate Variable Analysis. R package version 3.30.0., https:\/\/doi.org\/10.18129\/B9.bioc.sva (2019).","DOI":"10.18129\/B9.bioc.sva"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57542-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57542-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57542-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T01:01:38Z","timestamp":1670288498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-57542-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,17]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["57542"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-57542-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/652875","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,17]]},"assertion":[{"value":"3 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"605"}}